strong open, page-4

hi dynofish, (a snippet from forbes.com)
Investors are betting that the U.S. Food and Drug Administration will break with tradition and approve Dendreon's prostate cancer treatment. The company's stock, which traded below $4 in March, soared 30.6% on Monday, to $23.58, a $5.53 gain.

The shares have been rising since an FDA advisory panel recommended late last month that the government approve the drug. The FDA usually follows the advice of its advisers but is not bound to do so, and Dendreon (nasdaq: DNDN - news - people ) provides it with what could be viewed as a problematic situation. The drug actually failed to do what the clinical trials were designed to test for: slow the spread of prostate cancer. But instead, it has been effective in prolonging the lifespans of men who take it.

PGL 30 week trial results were fantastic so similar results for 48 weeks will send yanks crazy, there a only 3m shares on nasdaq & nobody wants to sell so i am waiting for final results to see what happens, cheers